VF
RLMD icon

Virtu Financial’s Relmada Therapeutics RLMD Stock Holding History

Virtu Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,640
Closed -$85K – 2201
2025
Q4 		$85K Buy
+17,640
New +$59.1K ﹤0.01% 1229
2020
Q3 		– Sell
-5,445
Closed -$244K – 1439
2020
Q2 		$244K Buy
+5,445
New +$230K 0.03% 639

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Virtu Financial's RLMD Position: Q1 2026 in Review

Virtu Financial sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 17,640 shares — an estimated $85K sold.

Virtu Financial first reported a position in RLMD in Q2 2020 and held it in 2 quarters. The position peaked at $244K in Q2 2020. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Virtu Financial reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 17,640 Relmada Therapeutics shares in Q1 2026, an estimated $85K.
  • Virtu Financial first reported a position in Relmada Therapeutics in Q2 2020 and held it in 2 quarters.
  • Virtu Financial's Relmada Therapeutics position peaked at $244K in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.